- Home
- MRSN vs VTGN Comparison
MRSN vs VTGN Comparison
Compare MRSN & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- VTGN
- Stock Information
- Founded
- MRSN 2001
- VTGN 1998
- Country
- MRSN United States
- VTGN United States
- Employees
- MRSN N/A
- VTGN N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- MRSN Health Care
- VTGN Health Care
- Exchange
- MRSN Nasdaq
- VTGN Nasdaq
- Market Cap
- MRSN 71.9M
- VTGN 82.7M
- IPO Year
- MRSN 2017
- VTGN N/A
- Fundamental
- Price
- MRSN $0.34
- VTGN $2.51
- Analyst Decision
- MRSN Buy
- VTGN
- Analyst Count
- MRSN 3
- VTGN 0
- Target Price
- MRSN $4.00
- VTGN N/A
- AVG Volume (30 Days)
- MRSN 3.1M
- VTGN 123.9K
- Earning Date
- MRSN 03-03-2025
- VTGN 02-13-2025
- Dividend Yield
- MRSN N/A
- VTGN N/A
- EPS Growth
- MRSN N/A
- VTGN N/A
- EPS
- MRSN N/A
- VTGN N/A
- Revenue
- MRSN $40,497,000.00
- VTGN $698,000.00
- Revenue This Year
- MRSN N/A
- VTGN N/A
- Revenue Next Year
- MRSN N/A
- VTGN N/A
- P/E Ratio
- MRSN N/A
- VTGN N/A
- Revenue Growth
- MRSN 9.88
- VTGN N/A
- 52 Week Low
- MRSN $0.34
- VTGN $2.22
- 52 Week High
- MRSN $4.64
- VTGN $5.74
- Technical
- Relative Strength Index (RSI)
- MRSN 29.11
- VTGN 39.56
- Support Level
- MRSN $0.41
- VTGN $2.58
- Resistance Level
- MRSN $0.42
- VTGN $2.69
- Average True Range (ATR)
- MRSN 0.04
- VTGN 0.16
- MACD
- MRSN -0.00
- VTGN -0.02
- Stochastic Oscillator
- MRSN 3.43
- VTGN 15.09
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.